- Home
- CHRS vs AMWL Comparison
CHRS vs AMWL Comparison
Compare CHRS & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- AMWL
- Stock Information
- Founded
- CHRS 2010
- AMWL 2006
- Country
- CHRS United States
- AMWL United States
- Employees
- CHRS N/A
- AMWL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- AMWL Retail: Computer Software & Peripheral Equipment
- Sector
- CHRS Health Care
- AMWL Technology
- Exchange
- CHRS Nasdaq
- AMWL Nasdaq
- Market Cap
- CHRS 112.5M
- AMWL 104.0M
- IPO Year
- CHRS 2014
- AMWL 2020
- Fundamental
- Price
- CHRS $0.76
- AMWL $6.80
- Analyst Decision
- CHRS Buy
- AMWL Hold
- Analyst Count
- CHRS 3
- AMWL 7
- Target Price
- CHRS $4.68
- AMWL $9.67
- AVG Volume (30 Days)
- CHRS 1.2M
- AMWL 37.1K
- Earning Date
- CHRS 08-07-2025
- AMWL 07-30-2025
- Dividend Yield
- CHRS N/A
- AMWL N/A
- EPS Growth
- CHRS N/A
- AMWL N/A
- EPS
- CHRS N/A
- AMWL N/A
- Revenue
- CHRS $272,251,000.00
- AMWL $261,675,000.00
- Revenue This Year
- CHRS N/A
- AMWL $2.87
- Revenue Next Year
- CHRS $132.69
- AMWL $6.72
- P/E Ratio
- CHRS $1.79
- AMWL N/A
- Revenue Growth
- CHRS 19.87
- AMWL 2.79
- 52 Week Low
- CHRS $0.66
- AMWL $5.00
- 52 Week High
- CHRS $2.43
- AMWL $12.95
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- AMWL 43.54
- Support Level
- CHRS $0.74
- AMWL $6.77
- Resistance Level
- CHRS $0.90
- AMWL $7.65
- Average True Range (ATR)
- CHRS 0.05
- AMWL 0.38
- MACD
- CHRS 0.01
- AMWL 0.01
- Stochastic Oscillator
- CHRS 13.56
- AMWL 26.09
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About AMWL American Well Corporation
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.